Effect of Risperidone on Cognitive Functions in Adolescents With ADHD and Behavioral Disturbances
NCT02906501 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 45
Last updated 2016-09-20
Summary
Introduction: The use of low dose risperidone and other antipsychotic drugs off-label as augmentation treatment for adolescents with Attention Deficit Hyperactivity Disorder (ADHD) and Disruptive Behavioral Disorder (DBD) has become widely common worldwide, usually to help control behavioral difficulties. While some argue that agents that block dopaminergic receptors may have a deleterious cognitive effect, others stress their moderating effects, which possibly improve function in all domains, including cognitive functions. Only a few studies have examined this topic, with inconclusive results.
Aim of study: To measure the effect of risperidone treatment on various cognitive functions in a population of ADHD diagnosed children and adolescents with normal IQ.
Design: The study is an observational prospective open label clinical controlled trial. The investigators will compare the performance in a battery of cognitive tasks using the Penn Web-Based Computerized Neurocognitive Battery (WebCNP) and the IGT, in children and adolescents diagnosed with ADHD, with and without risperidone.
Study population: Children and adolescents diagnosed with ADHD, 8-17 years old, may be eligible for this study. We will recruit subjects who their psychiatrist is considering rispieridone treatment, those who are already treated with risperidone and subjects with only stimulants treatment. All pharmacological treatment is supervised and prescribed to subjects by their personal psychiatrist unrelated to the study.
Significance: Better knowledge of the specific cognitive effects of this form of therapy will help us guide both clinical decisions, and recommended monitoring in daily clinical work.
Conditions
- ADHD
Interventions
- PROCEDURE
-
The Penn Web-Based Computerized Neurocognitive Battery
The Battery (PennCNP) of the Brain Behavior Laboratory at the University of Pennsylvania offers a range of probes of human neuropsychological functioning . It was designed for neuropsychological measurement of major cognitive domains. The WebCNP is administered using clickable icons on desktop or laptop computers, in a fixed order. Administrating the tests in a standard fashion fostering optimal performance without aiding the participant is required. For each domain, accuracy and speed are computed. Full battery completion takes approximately 2 hours. Each test begins with a practice module, to assure understanding of the instructions.
- PROCEDURE
-
The Iowa Gambling Test (IGT)
The essential feature of this task is that it mimics real-life situations in the way it factors uncertainty, reward and punishment. The task involves four decks of cards, named A, B, C and D. The goal is to maximize profit on a loan of play money. Subjects are required to make a series of 100 card selections, but are not told ahead of time how many card selections they are going to be allowed to make. Cards can be selected one at a time, from any deck, and subjects are free to switch from any deck to another, at any time and as often as they wish. The decision to select from one deck or another is largely influenced by schedules of reward and punishment. These schedules are pre-programmed and known to the examiner, but not to the subject (Bechara et al., 1994, 1999a).
Sponsors & Collaborators
-
Shalvata Mental Health Center
lead OTHER
Eligibility
- Min Age
- 8 Years
- Max Age
- 17 Years
- Sex
- MALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2016-09-30
- Primary Completion
- 2017-09-30
- Completion
- 2018-03-31
Countries
- Israel
Study Locations
More Related Trials
-
A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation
NCT00250354 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Effectiveness and Safety of Risperidone as add-on Therapy to Mood Stabilizers in the Treatment of Manic Episodes Associated With Bipolar Disorder
NCT00253149 ·Status: COMPLETED ·Phase: PHASE3
-
A Prospective Study of Risperdal (Risperidone) for the Treatment of Behavioral Disorder Following Psychological Therapy for Challenging Behavior in Learning Disabled Children
NCT00254930 ·Status: COMPLETED ·Phase: PHASE3
-
Risperidone Treatment In Children With Autism Spectrum Disorder And High Levels Of Repetitive Behavior
NCT01171937 ·Status: COMPLETED ·Phase: PHASE2
-
Treatment of Autism in Children and Adolescents
NCT00005014 ·Status: COMPLETED ·Phase: PHASE3
-
The Efficacy and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia
NCT00034749 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Efficacy and Safety of Risperidone in the Prevention of Relapse in Children and Adolescents With Conduct and Other Disruptive Behavior Disorders
NCT00236444 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Effectiveness and Safety of Risperidone in the Treatment of Behavioral Disturbances in Patients With Dementia
NCT00249145 ·Status: COMPLETED ·Phase: PHASE3
-
Psychosocial Therapy and Risperidone Treatment in Work Performance in Recent-Onset Schizophrenia
NCT00333177 ·Status: COMPLETED ·Phase: PHASE4
-
Effects of Atypical Antipsychotics on Brain Function in Children and Teens With Conduct Disorders
NCT01867398 ·Status: TERMINATED
-
A Study of the Effectiveness and Safety of Risperidone in the Treatment of Adolescents With Schizophrenia
NCT00246285 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Effectiveness and Safety of Two Doses of Risperidone in the Treatment of Children and Adolescents With Autistic Disorder
NCT00576732 ·Status: COMPLETED ·Phase: PHASE4
-
One Year Drug Treatment in First-Episode Schizophrenia
NCT00159081 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Risperidone Oral Solution Combination Clonazepam Versus Haloperidol Intramuscular (IM) Injection for Treatment of Acute Psychotic Agitation in Schizophrenia
NCT00859872 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol and Placebo in Patients With Chronic Schizophrenia
NCT00249132 ·Status: COMPLETED ·Phase: PHASE3
-
Research and Evaluation of Antipsychotic Treatment in Community Behavioral Health Organizations
NCT01181960 ·Status: COMPLETED
-
Evaluation of the Effects of Treatment of Psycho-stimulant and Cannabis-dependent Users in Israel
NCT01510015 ·Status: UNKNOWN ·Phase: NA
-
A Study of the Effectiveness and Safety of Risperidone Versus Placebo as add-on Therapy to Mood Stabilizers, in the Treatment of Manic Episodes Associated With Bipolar Disorder.
NCT00250367 ·Status: COMPLETED ·Phase: PHASE3
-
Study To Assess Differential Sensitivity Of 2 Spatial Working Memory Tests In Schizophrenics Treated With Risperidone
NCT00174200 ·Status: COMPLETED ·Phase: NA
-
A Study of the Effectiveness and Safety of Risperidone Compared With Haloperidol in Patients With Chronic Schizophrenia
NCT00249119 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Effectiveness and Safety of Risperidone Compared With Placebo in the Treatment of Manic Episodes Associated With Bipolar I Disorder, and the Maintenance of Anti-manic Effectiveness of Risperidone Compared With Haloperidol
NCT00253162 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of Ketamine and Risperidone on Cognition
NCT01140620 ·Status: COMPLETED ·Phase: PHASE4
-
Risperidone Pharmacokinetics in Children With Pervasive Developmental Disorder (PDD)
NCT00147394 ·Status: COMPLETED ·Phase: PHASE1
-
An Efficacy and Safety Study of Extended-Release (ER) Paliperidone in Adolescent Participants With Schizophrenia
NCT01009047 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Effectiveness and Safety of Risperidone Versus Placebo in the Treatment of Behavioral Disturbances in Patients With Dementia
NCT00253123 ·Status: COMPLETED ·Phase: PHASE3